Literature DB >> 15833426

Congenital muscular dystrophy with glycosylation defects of alpha-dystroglycan in Japan.

Hiroshi Matsumoto1, Yukiko K Hayashi, Dae-Son Kim, Megumu Ogawa, Terumi Murakami, Satoru Noguchi, Ikuya Nonaka, Tomoyuki Nakazawa, Takiko Matsuo, Satoshi Futagami, Kevin P Campbell, Ichizo Nishino.   

Abstract

Glycosylation defects of alpha-dystroglycan (alpha-DG) cause various muscular dystrophies. We performed clinical, pathological and genetic analyses of 62 Japanese patients with congenital muscular dystrophy, whose skeletal muscle showed deficiency of glycosylated form of alpha-DG. We found, the first Japanese patient with congenital muscular dystrophy 1C with a novel compound heterozygous mutation in the fukutin-related protein gene. Fukuyama-type congenital muscular dystrophy was genetically confirmed in 54 of 62 patients. Two patients with muscle-eye-brain disease and one Walker-Warburg syndrome were also genetically confirmed. Four patients had no mutation in any known genes associated with glycosylation of alpha-DG. Interestingly, the molecular mass of alpha-DG in the skeletal muscle was similar and was reduced to approximately 90 kDa among these patients, even though the causative gene and the clinico-pathological severity were different. This result suggests that other factors can modify clinical features of the patients with glycosylation defects of alpha-DG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833426     DOI: 10.1016/j.nmd.2005.01.009

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  10 in total

1.  Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.

Authors:  Masaji Tachikawa; Motoi Kanagawa; Chih-Chieh Yu; Kazuhiro Kobayashi; Tatsushi Toda
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

2.  Effect of beta-dystroglycan processing on utrophin/Dp116 anchorage in normal and mdx mouse Schwann cell membrane.

Authors:  K Hnia; G Hugon; A Masmoudi; J Mercier; F Rivier; D Mornet
Journal:  Neuroscience       Date:  2006-06-02       Impact factor: 3.590

3.  A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis.

Authors:  Satomi Mitsuhashi; Aya Ohkuma; Beril Talim; Minako Karahashi; Tomoko Koumura; Chieko Aoyama; Mana Kurihara; Ros Quinlivan; Caroline Sewry; Hiroaki Mitsuhashi; Kanako Goto; Burcu Koksal; Gulsev Kale; Kazutaka Ikeda; Ryo Taguchi; Satoru Noguchi; Yukiko K Hayashi; Ikuya Nonaka; Roger B Sher; Hiroyuki Sugimoto; Yasuhito Nakagawa; Gregory A Cox; Haluk Topaloglu; Ichizo Nishino
Journal:  Am J Hum Genet       Date:  2011-06-10       Impact factor: 11.025

4.  Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.

Authors:  Ute Hehr; Goekhan Uyanik; Claudia Gross; Maggie C Walter; Axel Bohring; Monika Cohen; Barbara Oehl-Jaschkowitz; Lynne M Bird; Ghiat M Shamdeen; Ulrich Bogdahn; Gerhard Schuierer; Haluk Topaloglu; Ludwig Aigner; Hanns Lochmüller; Jürgen Winkler
Journal:  Neurogenetics       Date:  2007-09-29       Impact factor: 2.660

5.  Muscle protein alterations in LGMD2I patients with different mutations in the Fukutin-related protein gene.

Authors:  Lydia U Yamamoto; Fernando J Velloso; Bruno L Lima; Luciana L Q Fogaça; Flávia de Paula; Natássia M Vieira; Mayana Zatz; Mariz Vainzof
Journal:  J Histochem Cytochem       Date:  2008-07-21       Impact factor: 2.479

6.  Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutations.

Authors:  Katherine G Meilleur; Kristen Zukosky; Livija Medne; Pierre Fequiere; Nina Powell-Hamilton; Thomas L Winder; Abdulaziz Alsaman; Ayman W El-Hattab; Jahannaz Dastgir; Ying Hu; Sandra Donkervoort; Jeffrey A Golden; Ralph Eagle; Richard Finkel; Mena Scavina; Ian C Hood; Lucy B Rorke-Adams; Carsten G Bönnemann
Journal:  J Neuropathol Exp Neurol       Date:  2014-05       Impact factor: 3.685

7.  A novel POMT2 mutation causes mild congenital muscular dystrophy with normal brain MRI.

Authors:  Terumi Murakami; Yukiko K Hayashi; Megumu Ogawa; Satoru Noguchi; Kevin P Campbell; Masami Togawa; Takehiko Inoue; Akira Oka; Kousaku Ohno; Ikuya Nonaka; Ichizo Nishino
Journal:  Brain Dev       Date:  2008-09-19       Impact factor: 1.961

8.  A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity.

Authors:  Cecilia Jimenez-Mallebrera; Silvia Torelli; Lucy Feng; Jihee Kim; Caroline Godfrey; Emma Clement; Rachael Mein; Stephen Abbs; Susan C Brown; Kevin P Campbell; Stephan Kröger; Beril Talim; Haluk Topaloglu; Ros Quinlivan; Helen Roper; Anne M Childs; Maria Kinali; Caroline A Sewry; Francesco Muntoni
Journal:  Brain Pathol       Date:  2008-08-07       Impact factor: 6.508

9.  Utility of Immunohistochemistry and Western Blot in Profiling Clinically Suspected Cases of Congenital Muscular Dystrophy.

Authors:  Radhika Mhatre; Deepha Sekar; Jessiena Ponmalar; Madhu Nagappa; Preethish-Kumar Veeramani; Kiran Polavarapu; Seena Vengalil; Nalini Atchayaram; Gayathri Narayanappa
Journal:  Ann Indian Acad Neurol       Date:  2020-07-24       Impact factor: 1.383

10.  First Identification of Compound Heterozygous FKRP Mutations in a Korean Patient with Limb-Girdle Muscular Dystrophy.

Authors:  Hyung Jun Park; Jung Hwan Lee; Ha Young Shin; Seung Min Kim; Ji Hyun Lee; Young Chul Choi
Journal:  J Clin Neurol       Date:  2015-08-21       Impact factor: 3.077

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.